Amyotrophic Lateral Sclerosis

ALS has both genetic and sporadic forms. The grounding supports genetic associations, including mutations and risk loci, and links the disease to protein mislocalization and aggregation, especially TDP-43. It also notes co-studied contributions from aging, the gastrointestinal microbiome, and neuronal plasticity, but does not support a single definitive cause.

The disease involves degeneration and replacement of motor neurons with fibrous astrocytes, along with atrophy of anterior spinal nerve roots and corticospinal tracts. Literature grounding also supports a role for neuroinflammation, protein aggregation, and impaired protein quality control, including ubiquitin-proteasome, chaperone-mediated autophagy, and macroautophagy pathways. TDP-43 mislocalization is a central pathological feature, and impaired mitophagy via PINK1/PARKIN signaling is also implicated in neurodegenerative mechanisms relevant to ALS.

Risk is increased by genetic susceptibility, including familial mutations and common or rare variant risk loci. The literature also highlights aging as a relevant associated mechanism. Other environmental and lifestyle risk factors are mentioned in the grounding, but not specified in the supplied text.

The supplied grounding does not support a specific standard-of-care treatment for ALS. It only indicates that the literature covers therapy and drug therapy, and that there is an unmet need for disease-modifying therapies. Stem cell-based approaches and therapies aimed at modulating neuroinflammation, protein aggregation, autophagy, or PINK1/PARKIN signaling are discussed as investigational or potential strategies rather than established care.